Efficacy and Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer and Autoimmune Diseases
ICIs may be effective in selected NSCLC patients with AIDs; however, careful monitoring is essential due to the risk of irAE and AID exacerbation.
Authors
- Yasuo Matuzawa
- Hiroki Wakabayashi (ORCID: https://orcid.org/0000-0002-8705-441X)
- Atsuhito Saiki (ORCID: https://orcid.org/0000-0003-4009-9386)
- Kazutoshi Isobe (ORCID: https://orcid.org/0000-0002-9995-2217)
- Kaichi Kaneko (ORCID: https://orcid.org/0000-0002-2082-6948)
- Kenta Takashima
Institutions
- Toho University (JP)
- Toho University Medical Center Sakura Hospital (JP)
Publication Details
- Journal
- Cureus
- Published
- 2025-05-29
- DOI
- https://doi.org/10.7759/cureus.85067
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05